Condition
Major Depression Severe
Total Trials
5
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 2 (1)
Trial Status
Not Yet Recruiting2
Enrolling By Invitation1
Terminated1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07503002Phase 1Not Yet Recruiting
Shortened LSD Intervention for Major Depressive Disorder
NCT07212946Phase 2CompletedPrimary
Ayahuasca and Esketamine for Major Depression
NCT07146269Not ApplicableEnrolling By Invitation
Virtual Reality-Augmented At-Home tDCS for Major Depression
NCT06748950Not ApplicableNot Yet Recruiting
Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling
NCT03254342Terminated
MRS and Medication Response: A Pilot Study
Showing all 5 trials